

CURRICULUM VITAE

Name: ZUO-FENG ZHANG

Office Address: Department of Epidemiology
UCLA School of Public Health
71-225 CHS, Box 951772
650 Charles E. Young Drive, South
Los Angeles, CA 90095-1772
(310) 825-8418 (Office)
(310) 206-6039 (Fax)
E-mail: ZFZHANG@UCLA.EDU

Education:

11/73 - 11/75 Yangzhou Secondary School of Hygiene
Diploma in Public Health, Yangzhou, China

09/78 - 08/83 Shanghai Medical University M.D., Shanghai, China

09/83 - 11/85 Shanghai Medical University, Department of Epidemiology
M.P.H. Program in Cancer Epidemiology, Shanghai, China

12/85 - 08/87 Shanghai Medical University, Department of Epidemiology
Ph.D. Candidate in Cancer Epidemiology, Shanghai, China

11/88 - 07/91 State University of New York at Buffalo
Memorial Roswell Park Cancer Institute Cancer Epidemiology
Ph.D., Buffalo, New York

Postdoctoral Training:

09/87 - 08/88 Post-Doctoral Research Fellow in Cancer Epidemiology
Division of Descriptive Epidemiology & Division of Biostatistics
International Agency for Research on Cancer (IARC), Lyon, France

Positions and Appointments:

12/69 - 11/73 Bare-foot Doctor, Nantong Farm

11/75 - 08/78 Preventive Doctor/Infectious Disease Epidemiologist
Schistosomiasis Control Program
Anti-epidemic Station of Yangzhou Area, Yangzhou, China

07/81 - 02/82 Intern, Departments of Internal Medicine and Surgery

Shanghai No. 8 General Hospital, Shanghai, China

09/83 - 08/87 Physician Researcher, Cancer Epidemiology
Department of Epidemiology, School of Public Health
Shanghai Medical University, Shanghai, China

09/87 - 08/88 Research Fellow in Cancer Epidemiology
Divisions of Descriptive Epidemiology & Biostatistics
International Agency for Research on Cancer (IARC), Lyon, France

11/88 - 07/91 Research Instructor in Cancer Epidemiology
Department of Social & Preventive Medicine
State University of New York at Buffalo, Buffalo

08/91 - 03/96 Assistant Member
Memorial Sloan-Kettering Cancer Center, New York

Assistant Attending Epidemiologist
Memorial Hospital, New York

Assistant Professor of Epidemiology in Public Health
Cornell University Medical College, New York

04/97 - 07/97 Associate Member/Professor
Memorial Sloan-Kettering Cancer Center, New York
Associate Attending Epidemiologist Memorial Hospital, New York

07/97 - 06/99 Associate Professor
Department of Epidemiology, School of Public Health
University of California, Los Angeles (UCLA)

07/99 - Present Professor
Department of Epidemiology, School of Public Health
University of California, Los Angeles (UCLA)

11/03 - Present Vice Chair
Department of Epidemiology, School of Public Health
University of California, Los Angeles (UCLA)

07/97 - Present Member, Jonsson Comprehensive Cancer Center
University of California, Los Angeles (UCLA)

07/97 - Present Scientific Director, UCLA Tumor Registry
University of California, Los Angeles (UCLA)

01/99 - Present Director

UCLA Molecular Genetic Epidemiology Training Program

01/01 - Present Co-Director of Epidemiology
Southern California Injury Research Center

01/01 - Present Director
Molecular Epidemiology Planning Program

07/02 - Present Co-Director, UCLA Center for Environment Genome

07/04 – Present Director, Alper Program of Environment Genomics

09/02 - Present Member, Board of Directors, American College of Epidemiology

04/04 - Present Director, Molecular Epidemiology and Gene-Environment Interaction
Program, UCLA Jonsson Comprehensive Cancer Center

06/03 – Present Senior Academic Advisor, Zijiang CDC

12/04-01/05 World Health Organization (WHO) Consultant, Western Pacific Region
Non-Communicable Disease Prevention and Control in People’s Republic
of China

Board Certification:

American College of Epidemiology

Scientific and Medical Societies:

Board of Directors, American College of Epidemiology (2001)
Member, Society of Epidemiologic Research
Member, American Society of Preventive Oncology
Faculty, New Investigator Workshop, ASPO (2000)
Member, International Epidemiological Association
Fellow, American College of Epidemiology (2000)
Board Member, Board of Directors, American College of Epidemiology
(2003-2006)
Member, Publication Committee, ACE (2000)
Member, International Genetic Epidemiology Society
Member, American Association of Cancer Research

University Committees:

Secretary, Faculty Executive Committee, School of Public Health
Member, Faculty Executive Committee, School of Public Health
Member, Admission Committee, Department of Epidemiology

Member, Student Affairs Committee, School of Public Health
Member, the Cancer Prevention Consensus Panel, Cancer Prevention Curriculum
Member, The Cancer Committee at UCLA
Chair, Space Committee, Department of Epidemiology
Chair, Search Committee for Position in Gene-Environment Interaction

Grants and Research Support:

1998 - 2004 Principal Investigator, T32 CA09142-21, Direct Cost: \$1,122,017
Cancer Epidemiology Training Program
NIH, National Institute of Cancer

2002 - 2005 Principal Investigator, ES011667, Direct Cost: \$450,000
Molecular Epidemiology and Gene-Environment Interaction
NIH, National Institute of Environment Health Sciences

2001 - 2006 Principal Investigator (R01), P50 CA90833-01, Direct Cost: \$1,300,000
Molecular Epidemiology of Lung Cancer
NIH, National Institute of Cancer

2001 - 2006 Co-Investigator, CA 091429 (PI: Braun), Direct Cost: \$272,338
Consented High-Performance Index/Retrieval Path System, NIH, NCI

2001 - 2006 Principal Investigator, DA03018 (PI: Tashkin), Direct Cost: \$399,314
Pulmonary Effects of Habitual Use of Marijuana, NIH, NIDA

2002 - 2007 Co-Investigator, U01 CA 96134 (PI: Mao), Direct Cost: \$990,000
Lung Cancer Chemo-prevention with Celecoxib in Ex-smokers.
NIH, NCI

2002 - 2007 Co-Investigator, U01 CA 96136 (PI: Belldegrun), Direct Cost: \$980,518
Bladder Cancer Chemo-prevention with Green Tea in Ex-smokers.
NIH, NCI

1999 - 2004 Co-Investigator, DA/CA 11386 (PI: Morgenstern), Direct Cost: \$304,108
Marijuana Use and the Risks of Lung and Other Cancers NIH, NIDA

Previous Grants:

1993 - 1996 Principal Investigator, R01-ES06718, Direct Cost: \$469,084
Molecular Epidemiology of Bladder Cancer
National Institute of Environmental Health Sciences

1997 - 1999 Principal Investigator, R03-DK/CA53653, Direct Cost: \$152, 000

H. Pylori, Malnutrition, and Gastric Cancer
National Institute of Diabetes, Digestive, and Kidney Diseases

- 1998 - 2000 Principal Investigator, 2 P30 CA16042-24, Direct Cost: \$150,000
Molecular Epidemiology of Cancer
Development Funds, Cancer Center Core Grant, NCI, NIH
- 1998 - 1999 Principal Investigator, (No Number), Direct Cost: \$29,954
Molecular Epidemiology of Prostate Cancer
Cancer Research Coordinating Committee, UC
- 1998 - 1999 Principal Investigator, (No Number), Direct Cost: \$25,775
Interaction between Cancer Susceptibility and Tobacco Smoking on the
Risk of Bladder Cancer.
JCCC Seed Money Support
- 1998 - 1999 Principal Investigator, (No Number), Direct Costs: \$24,998
Gene-nutrient interaction on the risk of prostate cancer.
Carolan
- 1996 - 1997 Principal Investigator, 2 P01 CA 29502, Direct Cost: \$23,000
Nutritional Factors for Cervical Neoplasia in Blacks
NIH/NCI, Clinical Nutritional Research Unit
- 1995 - 2000 Co-Investigator, 2 R01 CA 47538, Direct Cost \$164,048
Cooperative Network for Evaluation of Markers of Urinary Bladder
Cancer
National Cancer Institute
- 1996 - 2001 Co-Investigator, R01 DE12206, Direct Cost: \$300,000
Biomarkers of Oral Cancer Risk
National Cancer Institute
- 1993 - 1995 Principal Investigator, Direct Cost: \$90,908
Molecular/ Cellular Risk for Cervical Neoplasia in Blacks
New York Community Trust
- 1992 - 1995 Co-Principal Investigator, Direct Cost: \$150,000
Inheritance & Genetic Alterations in Gastric & GE Junction
Adenocarcinomas, Lawrence M. Gelb Foundation
- 1991 - 1995 Co-Investigator, POI-CA32617-09A1, Direct Cost: \$95,423
Smoking, Dieting & Other Risk Factors for Tobacco-Related Cancers
National Institute of Cancer
- 1994 - 1995 Co-Investigator, (\$100,000)

The Identification of Susceptibility to Colorectal Cancer in Humans
Institutional Funds

2001 - 2003 Co-Investigator, CCRP0000732V-20186 (PI:Berek), Direct Cost:
\$366,831
Nutrient-Gene Interaction in Ovarian Cancer
California Cancer Research Program

External Grant Review:

1996 Reviewer, the Aids Related Research Study Section, NIH/DRG
1997 Reviewer, Microbiological and Immunological Sciences Special Emphasis
Panel ZRG5 ARRD(3)
1995 Reviewer, Henry Ford Health System, Institutional Research Fund
2001 Reviewer, EDC2, NIH
2002 - 2003 Flight Attendant Medical Research Institute (FAMRI)
2002 Reviewer, National Cancer Institute Special Emphasis Panel ZCA1 GRB-
G (01), NIH
2003 Reviewer, Special Emphasis Panel, ZCA1 GRB-G (01): SPORE in
Ovarian and Breast Cancers, NCI
2003 - 2004 Reviewer, the Health Services Research Fund (HSRF) and the Health and
Health Services Research Fund (HHSRF), Hong Kong
2004 Reviewer, ZRGI HOP-D (02)M: Special Emphasis Panel: Member
Conflict: Cancer Epidemiology, NIH
2004 Reviewer, World Cancer Research Fund International, London, UK
2004 Reviewer, Epidemiology and Disease Control-2 (EDC-2) Study Section,
NIH
2005-2009 Member, Cancer Epidemiology Study Section (EPIC), NCI/NIH

Honors and Awards:

1980 - 1983 Awards for Excellent Medical Student each year by Shanghai Medical
University
1983 Rong-Lin's Prize (top 5/1000) by Shanghai Medical University
1985 - 1987 Post-Graduate Awards each year for Excellency by Shanghai Medical
University
1987 - 1988 Post-Doctoral Research Fellowship by International Agency for Research
on Cancer
1988 Second-Class Prize of Scientific & Technology Awarded by the Ministry
of Health for the Epidemiology of Cervical Cancer in Jingan County of
China

1996	The Harris P. Mosher Award by The American Laryngological, Rhinological and Ontological Society, aka The Triological Society
1996	Honorary Senior Fellow, Department of Public Health and Epidemiology, The University of Birmingham, Birmingham, U.K.
1998	Delta Omega, the IOTA Chapter at the School of Public Health, UCLA
1999	Honorary Guest Professor, School of Public Health, Beijing Medical University, China
1999	Honorary Visiting Professor, School of Public Health, Shanghai Medical University, China
1999	Honorary Guest Professor, Nantong Medical College, China 2001 Honorary Guest Professor, Nanjing Medical University 2001 Guest Professor, Yangzhou Medical University
2002	Honorary Guest Professor, Kunming Medical University
2002	Helene G. Brown Award for Excellence in Cancer Prevention and Control Research
2002	Senior Academic Advisor, Jiangsu CDC
2003	Senior Academic Advisor, Zijiang CDC

Administrative Responsibilities and Committees:

1982 - 1983	Vice President, Red-Cross Society, Shanghai Medical University
1992 - 1996	Member, Steering Committee, Risk Algorithm American Society of Preventive Oncology
1994 - 1997	Member, Psychosocial Task Force, MSKCC
1995 - 1997	Member, Nursing Research Advisory Council, MSKCC
1996 - Present	Member, Education Committee, American College of Epidemiology
1997 - Present	Member, Cancer Committee, UCLA Medical Center
1998 - 1999	Member, Student Affairs Committee, UCLA School of Public Health
1999 - Present	Member, Faculty Executive Committee, UCLA School of Public Health

1997 - 1998	Secretary, Faculty Executive Committee, UCLA School of Public Health
1997 - Present	Scientific Director, UCLA Tumor Registry, University of California, Los Angeles (UCLA)
1999 - Present	Director, UCLA/USC Molecular Genetic Epidemiology Training Program
2003 - 2005	Vice Chair, Department of Epidemiology, UCLA-School of Public Health
2003 - 2004	Chair, Search Committee for Public Health Genomics, UCLA-School of Public Health
2003 - 2004	Member, Environment Health Sciences Chair Search Committee
2003 - 2004	Member, Epidemiology Chair Search Committee

Community Services:

2001	Judges, National Youth Leadership Forum on Medicine- Public Health Symposium
2001	Guest, Talk Show, Tea Time, "Nutrition and Cancer" at KSCI Channel 18
	Guest, Talk Show, Tea Time, "Marijuana and Head and Neck Cancer" at KSCI Channel 18
	Guest, Talk Show, Tea Time, "Green Tea and Stomach Cancer" at KSCI Channel 18
	Guest, Talk Show, Tea Time, "Boron Intake and Prostate Cancer" at KSCI Channel 18
	Guest, Talk Show, News Analysis, "Green Tea and Cancer", Voice of America
	Guest, Talk show, Tea Time, "Bio-terrorism: Anthrax" 10/22 KSCI Channel 18
	Guest, Talk show, Tea Time, "Bio-terrorism: Smallpox and other potential biological weapons" 10/29 KSCI Channel 18

Graduate Student/Research Fellow Supervision:

Master's Trainees:

1993 - 1994	Dawn Norman, (Principal Thesis Supervisor), completed M.S. thesis entitled "Occupational Bladder Cancer and Mutations of the TP53 Gene", City University of New York, Hunter College, NY
1994 - 1995	Xiaoming Shu, (Principal Thesis Supervisor), M.A. thesis entitled "Cigarette Smoking and Chromosome 9 Microsatellite Instability in Bladder Cancer", California State University at Los Angeles, CA
1997 - 1998	Donna Catherine Gabriel, MS, MS Committee Member,

1997 - 1998	“Horseback Riding Deaths in California” Morris, Garret K., MS., MS Committee Chair Master’s Project: “GST P1 and Risk of Prostate Cancer”
1998 - 2000	Tsai, Chiao-Jung, M.S. , MS Committee Chair project: “H. pylori infection and stomach cancer”
1998 - 2000	Tsai, Pei-Jung, M.P.H., Academic Advisor project: “P53 serum antigen and risk of bladder cancer”

PhD Trainees (Serve as PhD committee member):

1994 - 1995	Andrew Nathan Freedman, (Outside Reader), completed Ph.D. thesis entitled "Etiological Risk Factors for TP53 Alterations in Colorectal Cancer", State University of New York at Buffalo, NY
1995 - 1997	Abby Stolper Bloch, Ph.D., (Dissertation Project Supervisor), “Diet and Lifestyle Factors and Polyp Occurrence in Adults at Varying Familial Risk”.
1997 - 1998	Robert G. Nelson, Ph.D., (Ph.D. committee member), “Epidemiologic studies of renal disease in Pima Indians with type 2 diabetes mellitus”
1997 - 1998	Maridel P. Borja, Ph.D. (Ph.D. committee member), “HIV/AIDS related risk profile of Filipino Male Commercial Sex Workers”. Dissertation Defense on 2/12/1998.
1997 - 1998	Caridad A. Asuncion Ancheta, Ph.D., Ph.D. Committee Member “Risk Factors of HIV/AIDS Among Returning Filipino Overseas Contract Workers”, Dissertation Defense on 8/19/1998.
1998 - 2000	Bonnie Blander Dean, PhD, PhD Committee member Project: “An epidemiologic assessment of risk factors in falls: intrinsic, psychological, and environmental risk factors among a diverse elderly population. Defended 2000.
1999-2004	Thomas Matthew Rice, PhD. in Epidemiology. Defended April 2004 Title: “The risk of fatal injury associated with light trucks during two-vehicle crashes: estimating equations and conditional maximum likelihood analysis of matched-pair cohort data.”
2000-2004	Chi-Hong Tseng, PhD in Biostatistics, PhD Committee Member Project: “Survival Analysis with Two Stage Design Studies”. Defended June 2004
2001-	Enwu Liu, PhD Candidate, PhD Committee Member Project: “Factors that influence client retention in methadone maintenance treatment program in China”
2000-	Anusha Krishnadasan, PhD Candidate, PhD Committee Project: “Epidemiology of Prostate Cancer in Rocketdyne study cohort”
1999-	Yingxu Zhao, PhD Candidate, PhD Committee Member Project: “Hierarchical regression analysis of Rocketdyne study.”

PhD Trainees (Serve as PhD committee chair):

Graduated

- 1997 - 2002 Hashibe, Mia, Ph.D., PhD Committee Chair
Project: “Smoking, drinking and other risk factors of oral pre-malignant conditions” PhD Committee Chair
- 1998 - 2002 Setiawan, Wendy, Ph.D. PhD Committee Chair
Project: “GST M1 and GST T1 and stomach cancer in Chinese population”
- 1997 - 2003 Susan M Higginbotham, PhD (PhD Committee Chair)
Project: “Dietary glycemic load and risk of breast and colorectal cancers”
- 1998 - 2004 Jui-Chun Hung, , PhD (PhD Committee Chair)
Project: “Tobacco consumption, genetic susceptibility, gene-environment interaction and lung cancer risk.”

PhD Candidates

- 1999 - Present Taylor L. McAfee, PhD Candidate (PhD Committee Chair)
DNA repair and risk of upper GI cancers
- 1999 - Present Nai-Chieh Yuko You, PhD Candidate (PhD Committee Chair)
ADH2 and ALDH2 and risk of esophageal cancer
- 2000 - Present Yan Cui, MD, MS, PhD Candidate (PhD Committee Chair)
Epidemiology of Stomach and Esophageal Cancer
- 1999 - Present Binh Yang, PhD Candidate (PhD Committee Chair)
Molecular epidemiology of liver cancer
- 1999 - Present Yuan-Chin Amy Lee, PhD Candidate (PhD Committee Chair)
Phases I and II genes and lung cancer
- 2001 - Present Yu-Ching Yang, PhD student (PhD Committee Chair)
Molecular Markers in Breast Cancer
- 2002 - Present Menghua Tao, MD, PhD student (PhD Committee Chair)
Epidemiology of Endometrial Cancer
- 2001 - Present Rita Velikina, PhD Student (PhD Committee Chair)
Epidemiology of Oral Premalignant lesions in minority population
- 2003 - Present Shu-Chun Chuang, MS, PhD Student (PhD Committee Chair)
- 2004 - Present Naja Rod Nielsen, PhD Student (PhD Committee Chair)

PhD Students (Passed written qualifying examination)

- 2000 - Present Leslie J. Ng, PhD Student (PhD Committee Chair)
Marijuana smoking and risk of HIV-related malignancies
- 2000 - Present Behnaz Pezeshki , PhD student (PhD Committee Chair)
Molecular Epidemiology of Head and Neck Cancers
- 2003-Present Chun Chao, PhD Student (PhD Committee Chair)
- 2004-Present Shen-Chih Chang, PhD Student (PhD Committee Chair)

Post-Doctoral Trainees since 2000:

2000 - 2003	Wei Cao, MD, PhD, Post-Doctoral Fellow (Mentor) Methylation and Risk of Cancers
1999 - 2003	Gloria Mao, PhD, Post-Doctoral Fellow (Mentor) RAR, RXR and Risk of Prostate Cancer
2000 - 2002	Lisa Smith, PhD (Mentor) STD in Black population
1998 - 2004	James Sul, MD p53 polymorphisms and risk of stomach cancer
2001 - 2002	Lina Mu, PhD (Research mentor) Gene-Environment interaction on risk of upper GI cancers
2002 - 2003	Jingkou Zhao, MD, PhD Molecular epidemiology of four top cancers in Chinese population
2003 - 2004	Hua Lu, MD, PhD Dietary Factors and Risk of Upper GI Cancers
2004 - Present	Susan M Higginbotham, PhD
2004 - Present	Lin Cai, MD, PhD

Teaching Experience

09/83 - 8/87	Shanghai Medical University A course to second year medical students "Methods of Cancer Epidemiology" A course to graduate students in School of Public Health "The Application of Survival Analysis Methods in Cancer Epidemiology" A course to graduate students in medical science "The Application of Personal Computer in Medical Research"
01/89 – 7/91	State University of New York at Buffalo lecture to 120 second year medical students on "Prognoses, Clinical Trials & Survival Analysis (SPM600)" Lecture to graduate students on "Occupational Epidemiology: Assessment of Interaction & Confounding" Lecture to graduate and medical students on "Bare-Foot Doctor and Health Care System in China" Guest lecturer on the topic of "International Health Systems: China (BEH824)"
8/91 - 6/97	Memorial Sloan-Kettering Cancer Center Lecture in Biostatistics for Clinical Studies Core Course "Principles of Epidemiology: Study Design" Lecture in Clinical Research Methodology Core Course "General Study Design for Medical Studies"
8/91 - 6/97	Cornell University Medical College Guide Seminar Session for Medical Students

"Epidemiology in Medicine"

- 10/98 - Present University of California, Los Angeles
Graduate Students at UCLA School of Public Health
"Seminar in Epidemiology: Cancer (EPID 295, 2 Units)"
- 10/98 - Present University of California, Los Angeles
Graduate Students at UCLA School of Public Health
"Cancer Epidemiology (EPID 242, 4 Units)"
- 10/00 - Present University of California, Los Angeles
Graduate Students at UCLA School of Public Health
"Molecular Epidemiology of Cancer (EPID 243, 4 Units)"
- 10/01 - Present University of California, Los Angeles
Graduate Students at UCLA School of Public Health
"Cancer Epidemiology Methods (EPID 244, 2 Unites)"

National and International Courses:

- Summer 2002 Course Director and Instructor
One week Course on Molecular Epidemiology of Cancer (English)
Nanjing Medical University
People's Republic of China
- Summer 2003 Course Director and Instructor
One week course on Theory and Practice of Epidemiology
Kunming Medical College, Yuennan Province
People's Republic of China
- Summer 2004 Course Director and Instructor
One week course on Molecular Epidemiology of Cancer
Mexico National Institute of Public Health
Cuernavaca, Morelos, Mexico
- December 2004 Course Director and Instructor
WHO Training on Chronic Diseases Prevention and Control
Jiangsu CDC
Suzhou, Jiangsu, People's Republic of China

Symposium:

- November 15, 2002 Co-Organizer and Speaker
Symposium on Gene-Environment Interactions, UCLA Center for
Environmental Genome. Organizer and Speaker, Mission Inn, Riverside

April 15, 2005 Organizer
Symposium on Advances of Molecular Epidemiology and Gene-
0Enmvironmental Interaction
UCLA Guest House

External Journal Review:

Reviewer, International Journal of Epidemiology
Reviewer, Nutrition and Cancer
Reviewer, Cancer Epidemiology Biomarkers & Prevention
Reviewer, Cancer Detection and Prevention
Reviewer, Cancer
Reviewer, Gynecologic Oncology, An International Journal
Reviewer, Annals of Epidemiology
Reviewer, Asian American and Pacific Islander Journal of Health
Referee, Journal of Epidemiology and Community Health
Reviewer, Oncology Research, An International Journal
Reviewer, Journal of Urology
Reviewer, Journal of Clinical Oncology
Reviewer, Kluwer Academic Publishers
Reviewer, International Journal of Cancer
Reviewer, Prostate Cancer and Prostatic Diseases
Reviewer, Preventive Medicine
Reviewer, American Journal of Epidemiology
Reviewer, Cancer Causes and Control

Invited seminars/lectures:

1. Risk Factors of Cervical Cancer in A Rural Chinese Population, A Case-Control Study. International Agency for Research on Cancer, Lyon, France, 7/1988
2. The Epidemiology of Cervical Cancer: Results from a Cohort Study. Memorial Sloan-Kettering Cancer Center, New York, 2/1991
3. Prognosis, Clinical Trials and Survival Analysis. The State University of New York at Buffalo Medical School, Buffalo, 10/1991
4. Descriptive Epidemiology of Head and Neck Cancer. Craig Wiseman Memorial Lecture, North Shore University Hospital, New York, 11/1991
5. The Epidemiology of Head & Neck Cancer. Head & Neck Conference, MSKCC, 2/1992
6. Nutritional Epidemiology, Nurse Group at Head & Neck Service, MSKCC, 6/1992

7. Molecular epidemiology of bladder cancer. Shanghai Medical University, Shanghai, 12/1992
8. The Gene-environmental Interaction: p53 Overexpression and Smoking on the Risk of Bladder Cancer. Opening lecture of Epidemiology Colloquium Series at the School of Public Health, Columbia University, New York City, 9/1993
9. The Epidemiology of Adenocarcinomas of Esophagus and Gastric Cardia. Epidemiology Rounds, Epidemiology Service, MSKCC, New York, 9/1993
10. Principles of Epidemiologic Study Design. In the course of "Biostatistics for Clinical Investigators", MSKCC and Cornell Graduate School of Medical Science, New York, 10/1993
11. Epidemiologic Study Designs. Internal Seminar, Department of Epidemiology & Biostatistics, MSKCC, New York, 1/1994
12. Molecular Epidemiology of Superficial Bladder Cancer. Mt Sinai School of Medical, New York, NY, 2/1994
13. Smoking and Bladder Carcinogenesis. Research Rounds of Division of Nursing, MSKCC, 1/1995
14. Epidemiology of Bladder Cancer. GU/H&N Research Conference, MSKCC, 2/1995
15. Molecular Epidemiology of Head and Neck Cancer, Head and Neck Research Conference. MSKCC, 5/95
16. Cancer Registry Statistics. Metropolitan New York Cancer Registrars Association, New York, 9/95.
17. Molecular Epidemiology of Cancer. New York University Medical School, New York, 11/95.
18. Adenocarcinomas of Esophagus and Gastric Cardia: the Role of diet. Epidemiology Research Seminar, Epidemiology Service, MSKCC, New York, 1/1996
19. Bladder Cancer Biomarkers, University of Birmingham, UK, 2/16, 1996
20. Methodological Issues in the Use of Tumor Markers in Epidemiology at "Methodological Issues in the Use of Biomarkers in Cancer Epidemiology" Workshop at International Agency for Research on Cancer, Lyon, France, 2/20-2/23, 1996

21. Nutritional Factors for Adenocarcinoma of esophagus and gastric cardia. Clinical Nutrition Research Unit, Cornell Medical School, Rockefeller University and Memorial Sloan-Kettering Cancer Center, 3/5, 1996
22. Molecular Epidemiology of Bladder Cancer. Dartmouth Medical College. Hanover, NH, 3/1996
23. Smoking, p53 overexpression, Chromosome 9 alterations in Bladder Cancer. Yale University Medical School. New Haven, CT, 4/1996
24. Epidemiology of Bladder Cancer. Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, 4/1996
25. Smoking and Mutational Pattern of TP53 gene in Bladder Cancer. School of Public Health, UCLA, CA, 5/1996
26. Bladder Cancer Epidemiology. Mayo Clinic, Rochester, Minnesota, 5/1996
27. TP53 mutation, GST M1, and Smoking in Bladder Cancer. Fox Chase Cancer Center, Philadelphia, 6/1996
28. Development of Molecular Epidemiology of Bladder Cancer, Department of Environmental Health, School of Medicine, University of Cincinnati, Cincinnati, 2/1997
29. Molecular Epidemiology of Bladder Cancer. Arizona Cancer Center, Tucson, Arizona, 10/1997
30. Molecular epidemiology and biomarkers of Cancer. Specialty Laboratory. Los Angeles, CA, 5/1998.
31. Molecular epidemiology of Bladder Cancer, Beijing Medical University, Beijing, China, 1999
32. Gene-environmental interaction on the risk of cancer, Nantong Medical University, 1999.
33. TP53 mutations and smoking on the risk of bladder cancer, Chinese Society of Preventive Oncology Conference, 1999.
34. Marijuana smoking and increased risk of squamous cell carcinoma of the head and neck. FASEB Summer Research Conference: Pulmonary Pathophysiology and Immune Consequences of Smoked Substance Abuse. Copper Mountain, CO, 1999
35. Case-control studies of associations between marijuana and risk of head and neck and lung cancer FASEB Summer Research Conference: Pulmonary Pathophysiology and Immune Consequences of Smoked Substance Abuse. Copper Mountain, CO, 1999

36. Essential Elements of Effective Screening. Schweitzer Regional Conference on Screening for Breast and Cervical Cancer, the Albert Schweitzer Institute, the Open Society Institute and the Network Women's Program Budapest, Hungary, December 4-7, 2000
37. Effective Screening Methodologies: Breast Cancer. Schweitzer Regional Conference on Screening for Breast and Cervical Cancer, the Albert Schweitzer Institute, the Open Society Institute and the Network Women's Program Budapest, Hungary, December 4-7, 2000
38. Effective Screening Methodologies: Cervical Cancer. Schweitzer Regional Conference on Screening for Breast and Cervical Cancer, the Albert Schweitzer Institute, the Open Society Institute and the Network Women's Program Budapest, Hungary, December 4-7, 2000
39. Gene-environment interaction on the risk of cancer. 3rd Annual Symposium "Cancer Prevention & Control In Asian Populations" October 16, 2001, Radisson Wilshire Plaza Hotel Los Angeles, California, 10/16, 2001
40. Overview of the application of molecular susceptibility markers in chemoprevention. Chemoprevention and Molecular Epidemiology Workshop, UCLA Jonsson Comprehensive Cancer Center, Division of Cancer Prevention and Control, 10/2, 2001
41. Marijuana Smoking and Head and Neck Cancer Risk. NIDA Workshop on Clinical Consequences of Marijuana, Rockville, Maryland, August 13-14, 2001
42. Cigarette smoking, Cancer Susceptibility and Risk of Lung Cancer: A population-Based Case-Control Study. NCI SPORE Workshop. 2001.
43. Environmental exposure, genetic polymorphisms and instability (or gene-environmental interaction) on the risk of cancers. 16th Asia Pacific Cancer Conference, Manila, Philippine, 2001.
44. H. Pylori infection, genetic susceptibility and stomach cancer in Chinese and US population. 16th Asia Pacific Cancer Conference, Manila, Philippine, 2001.
45. Green Tea Drinking and Reduced Risk of Gastric Cancer and Chronic Gastritis. Spring Harbor Laboratory Corporate Sponsor Program. Green Tea and Cancer, A critical Review May 14, 2002
46. Molecular Epidemiology of Cancer. UCLA-Fogarty Program meeting, Environmental and occupational health training needs on Mexico. May 28-29, 2002 at UNAM, Mexico City.
47. Gene-Nutrient Interaction and Risk of Cancers. W.M. Keck Nutrition and Genomics Symposium, October 3, 2002

48. Symposium on Gene-Environment Interactions, UCLA Center for Environmental Genome. Organizer and Speaker, Mission Inn, Riverside, November 15, 2002
49. SARS and Public Health. UCLA Symposium on the Scientific, Political, Social, and Economic Aspects of SARS. UCLA, May 29, 2003
50. Comparison of US and China Disease Monitoring system. International Advanced Symposium on SARS Prevention and Control. Jiangsu CDC, China, July 5, 2003
51. SARS Prevention and Control. Yuannan CDC, People's Republic of China, July 18, 2003
52. Public Health Issues, SARS, AIDS, and Cancer. Zhijiang CDC, People's Republic of China. July 25, 2003
53. Molecular Epidemiology and Gene-Environment Interaction. Gene, Symposium on Environment and Diseases. Harvard University, June 7-9, 2003.
54. Gene-Environment Interactions on the Risk of Cancers Mini-Symposium on Molecular Markers in Cancer Risk Assessment and Detection. University of Nebraska, August 12, 2003
55. Nutrient-Gene Interaction and Risk for Cancer. Symposium I. Nutrigenomics: Where Nutrition and Genetic Meet. American College of Nutrition Symposium on advances in Clinical Nutrition, 44th Annual Meeting, October 9-12, 2003, Nashville, Tennessee.
56. Green-Tea and Polymorphisms of DNA repair genes on the risk of stomach cancer. Vanderbilt University, 2003
57. Gene-Green Tea interaction on risk of gastric cancer in Chinese population. The fourth Annual AANCART Conference, Cancer in American Asian's Communities, Oct 24-25, 2003, Los Angeles
58. Environment-Gene Interaction and Risk of Cancer. The fourth Annual AANCART Conference, Cancer in American Asian's Communities, Oct 24-25, 2003, Los Angeles
59. Gene-Environment Interaction and Risk and Cancers. University of Pittsburgh, 2004

Publications:

I. Primary Papers:

1. Wu WZ, **Zhang ZF**, Yu SZ. Analysis of potential years of life lost on the mortality data of Suzhou from 1973 to 1983. *Chinese Journal of Preventive Medicine* 1986; 20(5):272 - 275.
2. **Zhang ZF**, Yu SZ. The application of potential years of life lost after eliminating the causes of deaths in epidemiology. *Acta Academiae Medicinae Shanghai*. 1986; 13(5):351 - 356.
3. Ding AH, Zhang SI, Sun SF, Li MW, **Zhang ZF**, Yu SZ. Transformation of cervical dysplasia. *Chinese Journal of Obstetrics and Gynecology* 1986; 21(2):96 - 99.
4. **Zhang ZF**, Yu SZ, Zhou GD. Indoor air pollution of coal fumes as a risk factor of stroke, Shanghai. *American Journal Public Health* 1988 Aug; 78(8):975 - 977.
5. **Zhang ZF**, Yu SZ. The application of relative survival rate in evaluating the effects of cervical cancer screening. *Chinese Journal of Hygienic Biostatistics* 1988; 5(5):1 - 4.
6. **Zhang ZF**, Yu SZ, Li WX, Bernard CK. Smoking, occupational exposure to rubber and lung cancer. *British Journal of Industrial Medicine* 1989; 46:12 - 15.
7. **Zhang ZF**, Parkin DM, Yu SZ, Esteve J, Yang XZ. Risk factors for Cancer of the cervix in a rural population in China. *International Journal of Cancer* 1989; 43:762-767.
8. **Zhang ZF**, Parkin DM, Yu SZ, Esteve J, Yang XZ, Day NE. Cervical screening attendance and its effectiveness in a rural population in China. *Cancer Detection and Prevention* 1989; 13:337-342.
9. Chen YX, Liao CS, Yang XZ, Zhang SJ, Xu JL, Jiao BG, Yu SZ, **Zhang ZF**, Ren QF. An analysis of epidemic factors in cervical cancer by conditional logistic regression model. *Chinese Journal of Medicine* 1990; 103(1):55-60.
10. Sarkis AS, Dalbagni G, Cordon-Cardo C, **Zhang ZF**, Sheinfeld J, Fair WR, Herr HW, Reuter VE. Nuclear Overexpression of p53 Protein in Transitional Cell Bladder Carcinoma: A Marker for Disease Progression. *Journal of National Cancer Institute* 1993; 85(6): 53-59.
11. Zeng ZS & **Zhang ZF**. Cholecystectomy and colorectal cancer in China. *Surgical Oncology* 1993; 2: 311-319.
12. Dalbagni G, Presti JC, Reuter VE, **Zhang ZF**, Sarkis AS, Fair WR, Cordon-Cardo C. Molecular genetic alterations of chromosome 17 and p53 expression in human bladder cancer. *Diagnostic Molecular Pathology* 1993; 2(1):4-13.

13. Simak R, Madersbacher S, **Zhang ZF**, and Maier U. The impact of ejaculation on serum prostate specific antigen. *Journal of Urology* 1993 Sept; 150: 895-897.
14. Sarkis AS, **Zhang ZF**, Cordon-Cardo C, Melamed J, Dalbagni G, Sheinfeld J, Fair WR, Herr HW, Reuter VE. P53 nuclear overexpression and disease progression in Ta bladder carcinoma. *International Journal of Oncology* 1993; 3: 355-360
15. **Zhang ZF**, Sarkis AS, Melamed J, Cordon-Cardo C, Dalbagni G, Aprikian AG, Pollack DM, Sheinfeld J, Fair WR, Herr HW, Reuter VE, Begg C. Tobacco smoking, Occupation, and p53 Nuclear Overexpression in Early Stage Bladder Cancer. *Cancer Epidemiology, Biomarkers, & Prevention* 1994; 3: 19-24.
16. Lianes P, Orlov I, **Zhang ZF**, Oliva MR, Reuter VE, Levine AJ, Cordon-Cardo C. Altered Patterns of MDM2 and TP53 Expression in Human Bladder Cancer. *Journal of National Cancer Institute* 1994 Sept 7; 86(17): 1325-1330.
17. Schultz P, Herr HW, **Zhang ZF**, Bajorin DF, Seidman AD, Sarkis AS, Fair WR, Scherr D, Bosl GJ, Scher HI. Neoadjuvant Chemotherapy for Invasive Bladder Cancer: Prognostic Factors for Survival of Patients Treated With M-VAC with 5-Year Follow-Up. *Journal of Clinical Oncology* 1994; 12(7):1394-1401.
18. Begg CB, **Zhang ZF**. Statistical Analysis of Molecular Epidemiology Studies Employing Case-Series. *Cancer Epidemiology, Biomarkers & Prevention* 1994 March; 3: 173-175.
19. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, **Zhang ZF**, Sheinfeld J, Fair WR, Herr HW, Reuter VE. Association of p53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder. *Journal of Urology* 1994 Aug; 152, 388-392.
20. **Zhang ZF**, Aprikian AG, Sarkis AS, Zeng ZS, Pollack D, Cordon-Cardo C, Fair WR, Begg CB. Factors associated with p53 nuclear accumulation in prostatic adenocarcinoma. *International Journal of Oncology* 1994; 4: 897-902.
21. Cordon-Cardo C, Dalbagni G, Saez GT, Oliva MR, **Zhang ZF**, J Rosai, Reuter VE, Pellicer A. P53 mutations in human bladder cancer: genotypic versus phenotypic patterns. *International Journal of Cancer* 1994; 56: 347-353.
22. Aprikian AG, Cordon-Cardo C, Fair WR, **Zhang ZF**, Bazinet M, Hamdy SM, Reuter VE. Neuroendocrine differentiation in metastatic prostatic adenocarcinoma. *Journal of Urology* 1994; 151(4): 914-919.
23. Aprikian AG, Fair WR, **Zhang ZF**. Prostate Adenocarcinoma in Men Younger than 50 Years. *American Cancer Society* 1994 Sept 15; 74(6): 1768-1777.

24. **Zhang ZF**, Begg C. Is trichomonas vaginalis a cause of cervical neoplasia? Results from a combined analysis of 24 studies. *International Journal of Epidemiology* 1994; 23(4): 682-690.
25. Zeng ZS, Cohen AM, Guillem JG, **Zhang ZF**. High Level of Nm23-H1 gene expression is associated with local colorectal cancer progression not with metastases. *British Journal of Cancer* 1994; 70, 1025-1030.
26. Aprikian AG, Sarkis AS, Fair WR, **Zhang ZF**, Fuks Z, Cordon-Cardo C. Immunohistochemical determination of p53 protein nuclear accumulation in prostatic adenocarcinoma. *Journal of Urology* 1994 May; 151, 1276-1280.
27. Zeng ZS, Sarkis AS, **Zhang ZF**, Klimstra DS, Charrytonowicz E, Guillem JG, Cordon-Cardo C, Cohen AM. P53 Nuclear Overexpression: An Independent Predictor of Survival in Lymph Node-Positive Colorectal Cancer Patients. *Journal of Clinical Oncology* 1994 Oct; 12(10): 2043-2050.
28. **Zhang ZF**, Vena JE, Zielezny M, Graham S, Haughey BP, Brasure J., Marshall JR. Occupational exposure to extreme temperature and risk of testicular cancer. *Archives of Environmental Health* 1995, 50(1): 13-18.
29. Zeng ZS, **Zhang ZF**, Sigurdson ER. Toxicity study of hepatic artery infusion chemotherapy with massive dose FUDR in rat. *Surgical Oncology* 1995, 4: 147-155.
30. Herr HW, Schwalb DM, **Zhang ZF**, Sogani PC, Fair WR, Whitmore WF Jr., Oettgen HF. Intravesical Bacillus Calmette-Guerin Therapy Prevents Tumor Progression and Death from Superficial Bladder Cancer: Ten-Year Follow-Up of a Prospective Randomized Trial. *Journal of Clinical Oncology* 1995 June, 13 (6): 1404-1408.
31. Scher HI, **Zhang ZF**, Cohen L, Kelly WK. Hormonally Re;apsed Prostatic Cancer: Lessons From the Flutamide Withdrawal Syndrome. *Advances in Urology* 1995, 8: 61-95.
32. **Zhang ZF**, Zeng ZS, Sarkis AS, Klimstra DS, Charytonowicz E, Pollack D, Vena J, Guillem JG, Marshall JR, Cordon-Cardo C, Cohen AM, Begg C. Family history of cancer, body weight and p53 Nuclear Over-expression in Duke's C Colorectal Cancer. *British Journal of Cancer* 1995, 71: 888-893.
33. Sarkis A, Bajorin D, Reuter V, Herr H, Netto G, **Zhang ZF**, Schultz P, , Cordon-Cardo C, Scher H. The Prognostic Value of p53 Nuclear Over-expression in Patients with Invasive Bladder cancer treated with Neoadjuvant MVAC. *Journal Clinical Oncology* 1995 June, 13 (6): 1384-1390.
34. **Zhang ZF**, Karpeh MS, Lauwers GY, Marrero AM, Pollack D, Cordon-Cardo C, Begg C. A case-series study of p53 nuclear overexpression in early stage stomach cancer. *New York Academy of Science* 1995 Sept 30, 768: 269-271.

35. Ghossein RA, Scher HI, Gerald WL, Kelly WK, Curley T, Amsterdam A, **Zhang ZF**, Rosai J. Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: Clinical implications. *Journal Clinical Oncology* 1995 May, 13 (5): 1195-1200.
36. **Zhang ZF**, Karpeh MS, Lauwers GY, Marrero AM, Pollack D, Cordon-Cardo C, Begg C. Risk Factors and p53 nuclear overexpression in early stage intestinal-type Adenocarcinoma of the stomach. *Cancer Detection and Prevention* 1995; 19 (2):156-164.
37. Begg C, **Zhang ZF**, Sun M, Herr H, Schantz SP. Methodology for evaluating incidence of second primary cancers with application to smoking-related cancers from SEER Program. *American Journal of Epidemiology* 1995; 142(6): 653-665.
38. Zeng ZS, Cohen AM, **Zhang ZF**, Stetler-Stevenson, Guillem JG. Elevated tissue inhibitor metalloproteinase-1 (TIMP-1) RNA in colorectal cancer stroma correlates with lymph node and distant metastases. *Clinical Cancer Research* 1995, 1: 899-906.
39. **Zhang ZF**, Graham S, Yu SZ, Marshall JR, Zielezny M, Chen YX, Sun M, Tang SL, Liao CS, Xu JL, Yang XZ. *Trichomonas vaginalis* and cervical cancer, a prospective study in China. *Annals of Epidemiology*, 1995 Aug, 5: 325-332.
40. Orlow I, Lacombe L, Hannon GJ, Serrano M, Dalbagni G, Pellicer I, Reuter VE, **Zhang ZF**, Beach D, Cordon-Cardo C. Deletion of p16 (INK4A/MTS1) and p15 (INK4B/MTS2) Genes in human bladder tumors. *Journal of National Cancer Institute* 1995 Oct 18, 87(20): 1524-1529.
41. Pollack D, Jubas J, **Zhang ZF**, Stellman SD, Harlap S. Reliability of smoking history in medical charts in relation to interview data. *International Journal of Oncology* 1995, 7: 1379-1382.
42. **Zhang ZF**, Kurtz RC, Yu Gp, Sun M, Harlap S. Calcium-channel blocker and cancer. *The Lancet* 1996; 348:1166-1167.
43. Scher HI, **Zhang ZF**, Nanus D, Kelly WK. Hormone and antihormone withdrawal: implications for the management of androgen-independent prostate cancer. *Urology* 1996 Jan, 47: 61-69.
44. Freedman AN, Michalek AM, Marshall JR, Mettlin CJ, Petrelli N, Black J, **Zhang ZF**, Satchidanand SKS, Asirwatham JE. Familial and Nutritional Risk Factors for p53 Overexpression in Colorectal Cancer. *Cancer Epidemiology, Biomarkers and Prevention* 1996 April, 5: 285-291.
45. Theodorescu D, Morash C, **Zhang ZF**, Fair WR, Russo P. Outcomes of initial surveillance of invasive squamous cell carcinoma of the penis and negative nodes. *The Journal of Urology* 1996 May, 155: 1626-1631.

46. **Zhang ZF**, Zhang ZZ, Yu SZ, Marshall JR, Zielesny M, Graham S, Chen YX, Yang XZ. Geographical distribution of risk factors and incidence of invasive cervical cancer in Southeast China. *Journal of Epidemiology & Community Health*. 1996, 50: 104-105.
47. Cloos J, Spitz MR, Schantz SP, Hsu TC, **Zhang ZF**, Hilde T, Braakhuis BJM, Snow GB. Genetic susceptibility to Head and Neck Squamous Cell carcinoma. *Journal of National Cancer Institute*. 1996 April 17, 88(8): 530-535
48. Rigas JR, Miller VA, **Zhang ZF**, Klimstra DS, Tong WP, Kris MG, Warrell RP Jr. Metabolic phenotypes retinoic acid and the risk of lung cancer. *Cancer Research* 1996 June 15, 56: 2692-2696.
49. Freedman AN, Michalek AM, Marshall JR, Mettlin CJ, Petrelli N, Black J, **Zhang ZF**, Satchidanand SKS, Asirwatham JE. The Relationship Between Smoking Exposure and p53 Overexpression in Colorectal Cancer. *British Journal of Cancer* 1996, 73: 902-908.
50. Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, **Zhang ZF**, Cordon-Cardo C. Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. *International Journal of Cancer* 1996, 69(2): 110-113.
51. Li MM, **Zhang ZF**, Reuter VE, Cordon-Cardo C. Chromosome 3 Allelic and Microsatellite Alternations in Transitional Cell Carcinoma of Urinary Bladder. *American Journal of Pathology* 1996 July, 149 (1): 229-235.
52. **Zhang ZF**. Epidemiology of *Trichomonas vaginalis*: A Prospective Study in China. *Sexually Transmitted Diseases* 1996, 23 (5): 415-424.
53. Lacombe L, Dalbagni G, **Zhang ZF**, Fair WR, Cordon-Cardo C, Herr HW, Reuter VE. Overexpression of the p53 protein in a high-risk population of Patients with superficial bladder cancer before and after BCG therapy and correlation to the clinical outcome. *Journal of Clinical Oncology* 1996 Oct; 14 (10): 2646-2652.
54. **Zhang ZF**, Kurtz RC, Sun M, Karpeh M, Yu GP, Gargon N, Fein JS, Georgopoulos SK, Harlap S. Adenocarcinomas of the esophagus and gastric cardia: medical conditions, tobacco, alcohol, and socioeconomic factors. *Cancer Epidemiology, Biomarkers, & Prevention* 1996 Oct; 5(10): 761-768.
55. Hardy DO, Scher H, Bodenreider T, Sabbatini P, **Zhang ZF**, Nanus D, Catterall JF. Androgen receptor CAG repeat lengths in prostate cancer patients: correlation with age of onset. *Journal of Clinical Endocrinology & Metabolism* 1996; 81 (12): 4400-4405.
56. Simak R, Wiener H, Foeger A, Susani M, **Zhang ZF**, Maier U, Marberger M. Cytophotometry in the monitoring of Bladder Cancer under intravesical chemotherapy. *European Urology* 1996; 29 (4): 391-398.

57. Yu GP, Ostroff JS, **Zhang ZF**, Tang J, Schantz SP. Smoking history and cancer patients survival: a hospital cancer registry. *Cancer Detection and Prevention*. 1997; 21 (6): 497-509.
58. Osman I; Scher H; **Zhang ZF**; Soos TJ; Hamza R; Eissa S; Khaled H; Koff A; Cordon-Cardo C. Expression of cyclin D1, but not cyclins E and A, is related to progression in bilharzial bladder cancer. *Clin Cancer Res* 1997; 3(12):2247-2251
59. Zheng WX, Sung CJ, Cao PC, **Zhang ZF**, Cai R, Godwin TA, Kramer EE, Lauchlan SC. Early occurrence and prognostic significance of p53 alteration in primary carcinoma of the fallopian tube. *Gyn. Oncology* 1997; 64: 38-48.
60. **Zhang ZF**, Kurtz RC, Yu GP, Sun M, Gargon N, Karpeh M Jr, Fein JS, Harlap S. Adenocarcinomas of the esophagus and gastric cardia: the role of diet. *Nutrition and Cancer* 1997; 27(3): 298-309.
61. Cordon-Cardo C., **Zhang Z.F.**, Dalbagni G, Drobnjak M, Charytonowicz E, Hu SX, Xu HJ, Heer H, Reuter V.E., Benedict WF. Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. *Cancer Research* 1997 April; 57: 1217-1221.
62. Osman I, Scher H, **Zhang ZF**, Pellicer I, Hamza R, Eissa S, Khaled H, Cordon-Cardo C. Alterations affecting the p53-control pathway in bilharzial-related bladder cancer. *Clinical Cancer Research* 1997; 3: 531-536.
63. **Zhang ZF**, Shu X.M., Cordon-Cardo C., Orlow I., Lu ML, Millon TV, Connolly_Jenks C, Dalbagni G, Lianes P., Lacombe L., Reuter VE, Scher H. Cigarette Smoking and Chromosome 9 alterations in bladder cancer. *Cancer Epidemiology, Biomarker, and Prevention* 1997 May; 6: 321-326.
64. Schantz SP, **Zhang ZF**, Spitz MS, Ming Sun, Hsu TC. Genetic susceptibility to head and neck cancer: interaction between nutrition and mutagen sensitivity. *Laryngoscope* 1997 June; 107: 765-781.
65. Cookson MS, Herr HW, **Zhang ZF**. Soloway S. Sogani PC. Fair WR. The treated natural history of high risk superficial bladder cancer:15-year outcome. *Journal of Urology*. 1997 July; 158(1):62-67.
66. Osman I, Scher H, Dalbagni G, Reuter V, **Zhang ZF**, Cordon-Cardo C. Chromosome 16 in primary prostate cancer: a microsatellite analysis. *International Journal of Cancer*. 1997; 71(4):580-584.
67. Muscad J. Stellman SD, **Zhang ZF**, Neugut AI, Wynder EL. Cigarette smoking and large cell carcinoma of the lung. *Cancer Epidemiology Biomarker & Prevention* 1997 July; 6: 477-480.

68. Ghossein RA, Rosai J, Scher HI, Seiden M, **Zhang ZF**, Sun M, Chang G, Berlane K, Krithivas K, Kantoff PW. Prognostic significance of detection of prostate-specific antigen transcripts in the peripheral blood of patients with metastatic androgen-independent prostatic carcinoma. *Urology* 1997; 50(1): 100-105.
69. **Zhang ZF**, Kurtz RC, Marshall JR. Cigarette smoking and esophageal and gastric cardia adenocarcinoma [Editorial]. *Journal of National Cancer Institute* 1997 Sept; 89 (17): 1247-1249.
70. Harrison LE, **Zhang ZF**, Karpeh MS, Sun M, Kurtz RC. The Role of Dietary Factors in the Intestinal and Diffuse histologic subtypes of gastric adenocarcinoma. *American Cancer Society* 1997; 80: 1021-1028.
71. Dalbagni G, Han W, **Zhang ZF**, Cordon-Cardo C, Saigo P, Fair WR, Herr H, Kim N, Moore MAS. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer. *Clinical Cancer Research* 1997 Sept; 3: 1593-1598.
72. Kanetsky PA, Mandelblatt J, Gammon M, **Zhang ZF**, Ramsey E, Wright TC, Thomas L, Matseoane S, Lazaro N, Felton HT, Sachdev RK, Richart RM, Curtin JP. Cigarette smoking and cervical dysplasia among non-hispanic black women. *Cancer Detect Prev* 1998; 22(2):109-119
73. Cordon-Cardo C, Koff A, Drobnjak M, Capodieci P, Osman I, Millard S, Gaudin P, Fazzari M, **Zhang ZF**, Massague J, Scher H. Distinct altered patterns of p27kip1 expression in benign prostatic hyperplasia and prostatic carcinoma. *Journal of National Cancer Institute* 1998 Sept 2; 90(17):1284-1291.
74. Zheng W; Khurana R; Farahmand S; Wang Y; **Zhang ZF**; Felix JC. p53 Immunostaining as a significant adjunct diagnostic method for uterine surface carcinoma: precursor of uterine papillary serous carcinoma. *American Journal of Surgical Pathology* 1998 Dec;22(12):1463-1473.
75. Dalbagni G, **Zhang ZF**, Lacombe L, Herr HW. Female urethral carcinoma: an analysis of treatment outcome and a plea for standardized management strategy. *British Journal of Urology* 1998, 82: 835-841
76. Orlow I, Lacombe L, Pellicer I, Rabbani F, Delgado R, **Zhang ZF**, Szijan I, Cordon-Cardo C. Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors. *Int Journal of Cancer* 1998;75(6):819-824.
77. Ghossein RA, Coit D, Brennan M, **Zhang ZF**, Wang Y, Bhattacharya S, Houghton A, Rosai J. Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. *Clinical Cancer Research* 1998 Feb;4(2):419-428.

78. Wu RL, Osman I, Wu XR, Lu ML, **Zhang ZF**, Liang FX, Hamza R, Scher H, Cordon-Cardo C, Sun TT. Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. *Cancer Research* 1998 Mar 15;58(6):1291-1297.
79. Freedman AN; Michalek AM; Weiss HA; **Zhang ZF**; Marshall JR; Mettlin CJ; Asirwatham JE; Petrelli NJ; Caporaso NE. Aspirin use and p53 expression in colorectal cancer. *Cancer Detection and Prevention* 1998;22(3):213-218.
80. Kanetsky PA, Mandelblatt J, Gammon M, **Zhang ZF**, Ramsey E, Dnistrian A, Norkus EP, Wright T. Dietary intake and blood levels of lycopene: Association with cervical dysplasia among non-Hispanic, Black women. *Nutrition and Cancer* 1998; 31(1):31-40
81. **Zhang ZF**, Morgenstern H, Spitz MR, Yu GP, Marshall JM, Tashkin D, Hsu TC, Schantz SP. Marijuana smoking and increased risk of squamous cell carcinoma of the head and neck. *Cancer Epidemiology, Biomarkers and Prevention* 1999 Dec; 8: 1071-1078.
82. Allen PJ; **Zhang ZF**; Coit DG. Surgical management of Merkel cell carcinoma. *Annals of Surgery* 1999 Jan;229(1):97-105
83. Yu GP, **Zhang ZF**, Hsu TC, Spitz MR, Schantz SP. Family history of cancer, mutagen sensitivity, and increased risk of head and neck cancer. *Cancer Letter* 1999; 146:93-101.
84. Cai L, Yu SZ, **Zhang ZF**. Relationship between Helicobacter pylori infection and gastric cancer. *Cancer Research on Prevention and Treatment*, 1999; 26(4): 247-249.
85. Scher HI, Kelly WMK, **Zhang ZF**, Ouyang P., Sun M., Schwartz M., Ding C., Wang W., Horak ID, Kremer AB. Post-therapy Serum Prostate-Specific Antigen Level and Survival in Patients With Androgen-Independent Prostate Cancer. *Journal of National Cancer Institute* 1999 Feb 3; 91 (3): 244-251.
86. **Zhang ZF**, Kurtz RC, Klimstra D, Yu GP, Sun M, Harlap S, JR Marshall. Helicobacter pylori Infection on the Risk of Stomach Cancer and Chronic Atrophic Gastritis. *Cancer Detection and Prevention* 1999 Sep 3; 23(5):357-367.
87. Sabbatini P; Larson SM; Kremer A; **Zhang ZF**; Sun M; Yeung H; Imbriaco M; Horak I; Conolly M; Ding C; Ouyang P; Kelly WK; Scher HI. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. *Journal of Clinical Oncology*. 1999 March; 17(3): 948-957.
88. Orlow I, Drobnjak M, **Zhang ZF**, Lewis J, Woodruff J, Murray Brennan M, Cordon-Cardo C. Alterations of the INK4A and INK4B Genes in Adult Soft Tissue Sarcomas: Effect on Survival. *JNCI* 1999 Jan 6; 91(1): 73-79.

89. Dalbagni G; **Zhang ZF**; Lacombe L; Herr HW. Male urethral carcinoma: analysis of treatment outcome. *Urology* 1999 Jun;53(6):1126-1132
90. Jacobson LP, Jenkins FJ, Springer G, Munoz A, Shah K, Phair J, **Zhang ZF**, Armenian H. Interaction of HIV-1 and HHV-8 infection on the incidence of Kaposi's sarcoma. *Journal of Infectious Diseases* 2000; 181: 1940-1949.
91. Hashibe M, Sankaranarayanan R, Mathew B, Kuruvilla B, Thomas G, Somanathan T, **Zhang ZF**. Alcohol drinking, Body mass index and the Risk of Oral Leukoplakia in an Indian Population. *International Journal of Cancer* 2000; 88:129-134.
92. Hashibe M, Mathew B, Kuruvilla B, Thomas G, Sankaranarayanan R, Parkin DM, **Zhang ZF**. Chewing tobacco, alcohol, and the risk of erythroplakia. *Cancer Epidemiology, Biomarker and Prevention*. 2000; 9(7): 639-645.
93. Cai L, Yu SZ, **Zhang ZF**. Helicobacter pylori infection and risk of gastric cancer in Changle County, Fujing Province, China. *World Journal of Gastroenterology*, 2000; 6(3): 374-376.
94. Setiawan VW, **Zhang ZF**, Yu GP, Li YL, Lu ML, Tsai CJ, Cordova D, Wang MR, Guo CH, Yu SZ, Kurtz RC. GSTT1 and GSTM1 Null Genotypes and the Risk of Gastric Cancer: A Case-control Study in Chinese Population. *Cancer Epidemiology, Biomarker and Prevention* 2000 Jan;9(1):73-80.
95. Zheng W, Luo F, Lu J, Baltayan A, Press MF, **Zhang ZF**, Pike MC. Reduction of BRCA1 Expression in Sporadic Ovarian Cancer. *Gynecol Oncol* 2000 Mar;76(3):294-300.
96. **Zhang ZF**, Morgenstern H, Spitz MR, Tashkin D, Yu GP, Hsu TC, Schantz SP. Environmental Tobacco Smoking, Mutagen Sensitivity, and Head and Neck Squamous Cell Carcinoma. *Cancer Epidemiology, Biomarker and Prevention* 2000; 9: 1043-1049.
97. Sung JC, Zheng Y, Quddus MR, Kang X, **Zhang ZF**, Lauchlan SC, Zheng W. p53 as a significant prognostic marker in endometrial carcinoma *International Journal of Gynecologic Cancer* 2000; 10: 119-127.
98. Kurtz RC, **Zhang ZF**. Gastric Cardia Cancer and Dietary Fiber. *Gastroenterology* 2001; 120(2): 568-570.
99. Setiawan VW, **Zhang ZF**, Yu GP, Lu QY, Li YL, Lu ML, Wang MR, Guo CH, Yu SZ, Kurtz RC, Hsieh CC. Protective effect of Green Tea on the Risks of Chronic Gastritis and Stomach Cancer. *International Journal of Cancer* 2001; 92: 600-604.
100. Setiawan VW, **Zhang ZF**, Yu GP, Lu QY, Li YL, Lu ML, Wang MR, Guo CH, Yu SZ, Kurtz RC, Hsieh CC. GSTP1 polymorphisms and gastric cancer in a high-risk Chinese population. *Cancer Causes and Control* 2001; 12 (8): 673-681.

101. Lu QY, Hung JC, Heber D, Go VLW, Reuter VE, Cordon-Cardo C, Scher HI, Marshall JR, **Zhang ZF**. Inverse Associations between Plasma Lycopene and Other Carotenoids and Prostate Cancer. *Cancer Epidemiology, Biomarkers and Prevention* 2001 July; 10: 749-756.
102. Dalbagni G, Genega E, Hashibe M, **Zhang ZF**, Russo P, Herr H, Reuter V. Cystectomy for bladder cancer: a contemporary series. *Journal of Urology* 2001 April; 165(3):1111-1116.
103. Yu SZ, **Zhang ZF**, Yu GP, Setiawan VW, Li YL, Wang MR, Guo CH, Hsieh CC. Epidemiology study of the influence of drinking green tea on gastric cancer and chronic gastritis. *China Oncology* 2001; 11 (1): 41-45.
104. Cai L, Yu SZ, Zhang ZF. Glutathione S-transferases M1, T1 genotypes and the risk of gastric cancer: a case-control study. *World Journal of Gastroenterology* 2001;7(4): 506-509.
105. Cai L, Yu SZ, **Zhang ZF**. Cytochrome P450 2E1 genetic polymorphisms and the risk of gastric cancer in a Chinese population. *World J Gastroenterology* 2001; 7(6): 792-795.
106. Hashibe M, Sankaranarayanan R, Thomas G, Kuruvilla B, Mathew B, Somanathan T, Parkin DM, **Zhang ZF**. Body Mass Index, Tobacco Use, Alcohol Drinking and The Risk Of Oral Submucous Fibrosis In Kerala, India. *Cancer Causes and Control* 2002; 13: 55-64.
107. Lu ML, Wikman F, Orntoft TF, Charytonowicz E, Rabbani F, **Zhang ZF**, Dalbagni G, Pohar KS, Yu GP, Cordon-Cardo C. Impact of Alterations Affecting the p53 Pathway in Bladder Cancer on Clinical Outcome, Assessed by Conventional and Array-based Methods. *Clinical Cancer Research* 2002 Jan; 8: 171-179.
108. Tam HT, **Zhang ZF**, Jacobson LP, Margolick JB, Chmiel JS, Rinaldo C, Detels R. Effect of Highly Active Antiretroviral Therapy on Survival among HIV-Infected Men with Kaposi Sarcoma or Non-Hodgkin Lymphoma. *International Journal of Cancer* 2002 Apr 20; 98(6):916-922.
109. Hashibe M, Ford DE, **Zhang ZF**. Marijuana Smoking and Head and Neck Cancer. *Journal of Clinical Pharmacology*. 2002 Nov;42 (11 Suppl):1S-5S.
110. Stellman SD, Chen Y, Muscat JE, Djordjevic MV, Richie JP Jr., Lazarus P, Thompson S, Altorki N, Berwick M, Citron ML, Harlap S, Kaur TB, Neugut AI, Olson S, Travaline JM, Witorsch P, **Zhang ZF**. Lung Cancer Risk in White and African Americans. *Annals of Epidemiology* 2003 Apr;13(4):294-302.

111. Cai L, Zheng ZL, **Zhang ZF**. Risk factors for the gastric cardia cancer: a case-control study in Fujian Province. *World Journal of Gastroenterology* 2003 Feb;9(2):214-218.
112. Mu LN, Zhou XF, Ding BG, Wang RH, **Zhang ZF**, Jiang QW, Yu SZ. Study on the protective effect of green tea on gastric, liver and esophageal cancers. *Chinese Journal of Preventive Medicine*. 2003 May;37(3):171-3.
113. Mu LN, Zhou XF, Ding BG, Wang RH, **Zhang ZF**, Jiang QW, Yu SZ. Genetic polymorphisms of p53 codon 72 and the risk of gastric cancer – a case-control study. *China Oncology*. 2003 13(1): 1-14.
114. Mu LN, Zhou XF, Ding BG, Wang RH, **Zhang ZF**, Chen CW, Wei GR, Zhou XM, Jiang QW, Yu SZ. A case-control study on drinking green tea and decreasing risk of cancers in the alimentary canal among cigarette smokers and alcohol drinkers. *Chinese Journal of Epidemiology*. 2003 Mar;24(3):192-195.
115. Cao W, Hashibe M, Rao JY, Morgenstern H, **Zhang ZF**. Comparison of methods for DNA extraction from paraffin-embedded tissues and buccal cells. *Cancer Detection and Prevention*. 2003 27(5): 397-404
116. Hashibe M, Jacob BJ, Thomas G, Ramadas K, Mathew B, Sankaranarayanan R, **Zhang ZF**. Socioeconomic status, lifestyle factors and oral premalignant lesions. *Oral Oncology* 2003; 39(7): 664-71.
117. Thomas G, Hashibe M, Jacob BJ, Ramadas K, Mathew B, Sankaranarayanan R, **Zhang ZF**. Risk Factors for Multiple Oral Premalignant Lesions. *International Journal of Cancer*. 2003; 107(2): 285-291.
118. Yu SZ, L Cai, Mu LN, **Zhang ZF**. The application of case-case study design in epidemiology. *Chinese Journal of Epidemiology*. 2003 May;24(5): 406-409.
119. Hashibe M, Gao T, Li G, Dalbagni G, **Zhang ZF**. Comparison of Bladder Cancer Survival Among Japanese, Chinese, Filipino, Hawaiian and Caucasian Populations in the United States. *Asian Pacific Journal of Cancer Prevention*. 2003; 4(3): 267-273.
120. Cui Y, **Zhang ZF**, Froines J, Zhao JK, Wang H, Yu SZ, Detels R. Air pollution and case fatality of SARS in the People's Republic of China: an ecologic study. *Environmental Health Environmental Health: A Global Access Science Source* 2003, 2:15.
121. Yang BH, Bray FI, Parkin DM, Sellors JW, **Zhang ZF**. Cervical Cancer as a Priority for Prevention in Different World Regions: an Evaluation Using Years of Life Lost. *International Journal of Cancer*, 2004, 10; 109(3): 418-24
122. Higginbotham S, **Zhang ZF**, Lee IM, Cook NR, Buring JE, Liu S. Dietary Glycemic Load and Breast Cancer Risk in the Women's Health Study. *Cancer Epidemiol Biomarkers Prev*. 2004 Jan;13 (1): 65-70.

123. Higginbotham S, **Zhang ZF**, Lee IM, Cook NR, Giovannucci E, Buring JE, Liu S; Women's Health Study. Dietary glycemic load and risk of colorectal cancer in the Women's Health Study. *J Natl Cancer Inst.* 2004 Feb 4;96(3):229-33.
124. Cui Y, Winton MI, **Zhang ZF**, Rainey C, Marshall JR, deKernion JB, Eckhert CD. Dietary Boron Intake and Prostate Cancer. *Oncology Reports.* 2004 Apr;11(4): 887-92.
125. Mao GE, Reuter VE, Cordon-Cardo C, Dalbagni G, Scher HI, deKernion JB, **Zhang ZF**, Rao JY. Decreased Retinoid X Receptor-Alpha Protein Expression in Basal Cells Occurs in the Early Stage of Human Prostate Cancer Development. *Cancer Epidemiology, Biomarkers and Prevention* 2004 Mar;13 (3): 383-390.
126. Jacob BJ, Straif K, Thomas G, Ramadas K, Mathew B, **Zhang ZF**, Sankaranarayanan R, Hashibe M. Betel quid without tobacco as a risk factor for oral precancers. *Oral Oncology* 2004, 40: 697-704.
127. Yang BH, Parkin DM, Cai L, **Zhang ZF**. Cancer burden and trends in the Asian Pacific Rim region. *Asian Pacific Journal of Cancer Prevention.* 2004; 5 (2): 96-117.
128. Mao GE, Morris G, Lu QY, Cao W, Reuter VE, Cordon-Cardo C, Dalbagni G, Scher HI, deKernion JB, **Zhang ZF**. Cigarette Smoking, Glutathione S-transferase P1 Ile105Val Polymorphism, cigarette smoking and Prostate Cancer. *Cancer Detection and Prevention* 2004, 28: 368-374
129. Zhang QZ, **Zhang ZF**, Rao JY, Sato D, Brown J, Messadi DV, Le D. Treatment with siRNA and Antisense Oligonucleotides Targeted to HIF-1 α Induced Apoptosis in Human Tongue Squamous Cell Carcinomas. *International Journal of Cancer.* 2004; 111; 849-857.
130. Mu LN, Ding BG, Chen CW, Wei GR, Zhou XF, Wang RH, Cai L, **Zhang ZF**, Jiang QW, Yu SZ. A case-control study on the relationship between methyl-tetra-hydrofolic acid reductase 677 gene polymorphism and the risk of stomach cancer. *Chinese Journal of Epidemiology.* 2004 Jun;25(6):495-8.
131. Cao W, Chen XF, Dai H, Wang H, Shen B, Chu D, McAfee T, **Zhang ZF**. Mutational Spectra of P53 in Geographically Localized Esophageal Squamous Cell Carcinoma Groups in China. *Cancer* 2004 June 23 15;101 (4):834-844.
132. Mu LN, Zhou XF, Ding BG, Wei GR, Chen CW, Chang J, Cai L, **Zhang ZF**, Jiang QW, Yu SZ. Exploration on the relationship between drinking-water types and the risks of three upper-GI cancers in South China. *Chinese Chronic Disease Prevention and Control.* 2004,12 (6):247-250
133. Lu QY, Jin YS, Zhang Q, **Zhang ZF**, Heber D, Go VL, Li FP, Rao JY. Ganoderma lucidum extracts inhibit growth and induce actin polymerization in bladder cancer cells in

- vitro. Cancer Letter. 2004 Dec 8;216(1):9-20.
134. Cai L, Binh Yang, Zhang ZF. Cancer Incidence and Mortality in Asian Pacific Rim. Tumor 2004.
 135. Wallerand H, Bakkar AA, De Medina SG, Pairon JC, Yang YC, Vordos D, Bittard H, Fauconnet S, Kouyoumdjian JC, Jaurand MC, **Zhang ZF**, Radvanyi F, Thiery JP, Chopin DK. Mutations in TP53, but not FGFR3, in urothelial cell carcinoma of the bladder are influenced by smoking: contribution of exogenous versus endogenous carcinogens. Carcinogenesis. 2005. 26(1):177-84.
 136. Hashibe M, Ritz B, Le, AD, Li G, Sankaranarayanan R, **Zhang ZF**. Radiotherapy for Oral Cancer as a Risk Factor for Second Primary Cancers. Cancer Letters 2005, 220: 185-195.
 137. Lu QY, Jin YS, Pantuck A, **Zhang ZF**, Heber D, Belldegrun A, Brooks M, Rao JY. Green Tea Extract Modulates Actin Remodeling via Rho Activity in an *in vitro* Multistep Carcinogenic Model. Clin Cancer Res. 2005 15;11(4):1675-83.
 138. Mu LN, Lu QY, Yu SZ, Jiang QW, Cao W, You NC, Zhou XF, Ding BG, Wang RH, Zhao J, Cai L, Rao JY, Heber D, **Zhang ZF**. Green tea and its interactions with other risk factors on the risk of stomach cancer in a Chinese population. International Journal of Cancer 2005; 116: 972-83.
 139. Lin Cai, Zong-Li Zheng, **Zuo-Feng Zhang**. Cytochrome P450 2E1 polymorphisms and the risk of gastric cardia cancer. World Journal of Gastroenterology 2005, 11(12): 1867-1871.
 140. Wei Cao, Lin Cai, **Zuo-Feng Zhang**, Minglan Lu, et al. Gene-environmental interaction between tobacco smoking and GSTP1 polymorphism on the risk of bladder cancer. Cancer 2005 (accepted 3/12)
 141. Cui Y, **Zhang ZF**, Morgenstern H, Greenland S, Tashkin DP, Mao J, Cozen W, Mack TM, Cao W. Polymorphism of xeroderma pigmentosum group G (XPG) and the risk of lung and head and neck cancers. Int J Cancer (in press)
 142. Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI, **Zhang ZF**. Radiotherapy for Primary Thyroid Cancer as a Risk Factor for Second Primary Cancers. Cancer Letters 2005 (in press)
 143. Sul J, Setiawan VW, Yu GP, Lu QY, Lu ML, Yu SZ, Mu LN, Kurtz RC, Cai L, **Zhang ZF**. P53 Codon 72 Polymorphisms: A Case-Control Study of Gastric Cancer and Potential Interactions. Cancer Letter 2005 (in press)
 144. Naja Rod Nielsen, **Zuo-Feng Zhang**, Eva Prescott, Tage Søndergaard Kristensen, Peter Schnohr, Morten Grønbaek. Self-perceived stress and risk of breast cancer, a prospective

cohort study in Denmark. British Medical Journal, 2005 (in press)

145. Setiawan VW, Yu GP, Lu QY, Lu ML, Yu SZ, Mu LN, Zhang JG, Kurtz RC, Cai L, Hsieh CC, **Zhang ZF**: Allium Vegetables and Risk of Stomach Cancer in a Chinese Population. Asian Pacific Journal of Cancer Prevention 2005 (6) (in press)
146. Zhang QZ, Tang XD, Lu QY, **Zhang ZF**, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1 α and VEGF expression in human tongue squamous cell carcinoma and HepG2 Cells. Molecular Cancer Therapeutics, 2005 (in press)
147. **Mu LN**, Chen CW, Wei GR, Cai L, Cao W, Zhang ZF, Jiang QW. Exploration on the Relationship Between MTHFR Gene Polymorphisms and the Risk of Primary Liver Cancer. Tumor, 2005 (in press)

II. Review, Chapter, Monographs, and Proceedings:

148. Cloos J, Spitz MR, Schantz SP, Hsu TC, **Zhang ZF**, Hilde T, Braakhuis BJM, Snow GB. Chapter 4. Genetic susceptibility to head and neck squamous cell carcinoma. In Cloos J (ed): Mutagen sensitivity: a phenotype reflecting susceptibility to head and neck squamous cell carcinoma. Amsterdam, 1996, pp. 56-67.
149. **Zhang ZF** & Steineck G. The epidemiology and etiology of bladder cancer. In Raghavan, Scher (eds): Principles and Practice of Genitourinary Oncology. J.B. Lippincott, New York, 1997, pp. 215-222.
150. **Zhang ZF**, Cordon-Cardo C, Rothman N, Freedman A, Taylor JA. Methodological issues in the use of tumor markers in cancer epidemiology. In Toniolo P, Boffetta P, Shuker D, Rothman N, Hulka B and Pearce N (eds): Application of biomarkers to cancer epidemiology. International Agency for Research on Cancer (IARC) Scientific Publication No. 142, 1997, 201-213.
151. **Zhang ZF**. Lung cancer. In Breslow L, Editor. Encyclopedia of Public Health. Macmillan Reference USA, Vol. 3, L-R, 2002; 702-704.
152. **Zhang ZF**. Molecular Epidemiology. (Qingwu Jing, Editor) Epidemiology Text Book for Graduate Students (in Chinese). 2003
153. Tsai H, Hemstreet GP, Seligson D, **Zhang ZF**, Rao JY Tissue microarray and quantitative fluorescence image analysis in tumor biomarker analysis. In Hayat MA editor. Handbook of Immunohistochemistry and in-situ Hybridization of Human Carcinomas: Molecular Genetics, Liver Carcinoma, and Pancreatic Carcinoma, Volume 3. Elsevier Science (2005 in press)
154. Mu LN, Cai L, Yu SZ, **Zhang ZF**. Study Design of Molecular Epidemiology. Fudan University Journal of Medical Sciences. 2005, 32 (1):190-193.

155. You NC and **Zhang ZF**. Nutrition and Gastric Cancer. (in Heber D, Editor. Nutritional Oncology, 2nd Edition) 2005 (in press)
156. Hashibe M, Straif K, Tashkin DP, Morgenstern H, Greenland S, **Zhang ZF**. Epidemiologic review of marijuana use and cancer risk. Alcohol 2005, 35: 265-275.

III. Letter to the Editor:

157. Schultz P, **Zhang ZF**, Scher H. Prognostic factors in bladder cancer after primary M-VAC (In Reply). Journal of Clinical Oncology 1995, 13 (1): 301-302.
158. **Zhang ZF**, Kurtz RC, Yu GP, Sun M, Harlap S. Calcium-channel blockers and cancer. The Lancet 1996, 348: 1166-1167.